Twist Bioscience Corp(TWST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 7:46 AM ET (Korea 10/26 20:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.22 | Insider Own | 2.77% | Shs Outstand | 65.8M | Perf Week | 5.4% |
| Market Cap | 9.21B | Forward P/E | - | EPS next Y | 38.79% | Insider Trans | -35.92% | Shs Float | 64.0M | Perf Month | -23.97% |
| Enterprise Value | 9.14B | PEG | - | EPS next Q | -0.38 | Inst Own | 121.41% | Short Float | 16.51% | Perf Quarter | 61.68% |
| Income | -0.14B | P/S | 21.33 | EPS this Y | -64.76% | Inst Trans | 3.05% | Short Ratio | 4.74 | Perf Half Y | 129.6% |
| Sales | 0.43B | P/B | 19.67 | EPS next 5Y | 12.43% | ROA | -20.78% | Short Interest | 10.57M | Perf YTD | 341.11% |
| Book/sh | 7.11 | P/C | 55.21 | EPS past 3/5Y | 31.51% 18.31% | ROE | -29.59% | 52W High | -36.32% ($219.71) | Perf Year | 339.59% |
| Cash/sh | 2.53 | P/FCF | - | Sales past 3/5Y | 22.76% 33.11% | ROIC | -25.76% | 52W Low | 500.52% ($23.30) | Perf 3Y | 778.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -53.86% | Gross Margin | 51.97% | Volatility(W/M) | 9.74% 9.73% | Perf 5Y | 19.17% |
| Dividend TTM | - | EV/Sales | 21.16 | Sales Y/Y TTM | 19.19% | Oper. Margin | -31.91% | ATR (14) | 14.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.38 | EPS Q/Q | -268.48% | Profit Margin | -31.66% | RSI (14) | 44.02 | Recom | 1.92 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.67 | Sales Q/Q | 23.24% | SMA20 | -12.84% ($160.53) | Beta | 2.24 | Target Price | $168.25 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2026/8/3 | SMA50 | -6.57% ($149.76) | Rel Volume | 0.83 | Prev Close | $135.47 |
| Employees | 979 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | -10.61% 3.37% | SMA200 | 62.82% ($85.94) | Avg Volume(3M) | 2.23M | Price | $139.92 |
| IPO | 2018/10/31 | Option/Short | Yes/Yes | Trades | 21117 | Volume | 1,857,988 | Change | 3.28% |
🧬 A synthetic biology company that manufactures silicon-based synthetic DNA. Using its proprietary silicon platform, it mass-produces synthetic genes and DNA libraries, and provides next-generation DNA sequencing tools, antibody discovery, and DNA data storage technology. A rapidly growing synthetic biology and genomics tools company.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded about as much as usual. That is 83% of its average volume.
TWST has a sound balance sheet but weak earning power
Of every $100 in sales, $31.91 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -64.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,133. Peers typically go for $897.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +19.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 121.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #26 of 595 in the industry
Based on market cap of $9B.
CORT#24 Corcept Therapeutics Inc $9B PER 205.1 
KRYS#25 Krystal Biotech Inc $9B PER 39.0 TWST#26 Twist Bioscience Corp $9B PER - 
KYMR#27 Kymera Therapeutics Inc $9B PER - 
CAI#28 Caris Life Sciences Inc $9B PER 86.0 
FAQ
What kind of company is TWST?
TWST belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TWST?
The market cap of TWST is approximately $9.2B, ranking 966 within its sector.
What is the 52-week high and low for TWST?
TWST has recorded a 52-week high of $219.71 and a low of $23.30.
